Judge Ruled Liquidia Infringed Patent for Yutrepia
The ruling forces Liquidia to update its drug labeling, impacting operational strategy for the company.
Updated on Oct. 5, 2026 in Healthcare
Live Poll
Should patent protections allow companies to force competitors to change drug labeling?
A federal court judge ruled that Liquidia infringed a United Therapeutics patent by including specific treatment instructions on the label for its drug, Yutrepia. The ruling could reshape the company's product strategy for treating pulmonary hypertension.
Why it matters
The decision creates immediate compliance and product labeling hurdles for Liquidia, forcing a strategic shift to avoid further infringement claims. United Therapeutics is now poised to pursue damages, increasing the financial and legal pressure on the competitor.
Liquidia recorded $304 million in revenue and $127 million in profit during the first six months of 2026. Following the ruling on patent 11,826,327, the company saw its market capitalization drop by $4 billion.
The players
Liquidia
A North Carolina-based biopharmaceutical company focused on developing and commercializing therapies for pulmonary hypertension.
United Therapeutics
A biotechnology company that develops medical therapies for chronic and life-threatening conditions, including pulmonary arterial hypertension.
Richard G Andrews
A U.S. District Court judge presiding over the federal patent infringement case in Delaware.
The details
Judge Richard G Andrews found that Liquidia's inclusion of instructions on the Yutrepia label for treating pulmonary hypertension associated with interstitial lung disease violated claims 1 and 14 of the patent held by United Therapeutics. To mitigate further legal exposure, Liquidia now plans to remove these specific treatment instructions from its product labeling. The firm is currently considering an appeal of the court's 55-page opinion.
Timeline
September 30, 2026: Judge Andrews issued his opinion on patent infringement.
October 7, 2026: Deadline for parties to reach an agreement on a remedy.
February 2042: United Therapeutics patent 11,826,327 expires.
Market Landscape
The ruling updates the competitive landscape previously altered by the 2022 US Patent and Trademark Office ruling on patent 10,716,793, which deemed the earlier patent unpatentable. It highlights the ongoing legal volatility surrounding proprietary drug labeling in the pulmonary hypertension market.
Operators in highly regulated sectors should monitor the outcome of the October 7 deadline, as it will establish a precedent for label-based patent enforcement. Businesses must audit their product labeling practices to ensure compliance with existing patents to avoid similar litigation risks.
The takeaway
The case underscores the necessity for companies to conduct rigorous patent reviews before finalizing product labels for high-growth medical therapies. Operators should track whether Liquidia proceeds with an appeal to understand the long-term impact on market access for similar drug formulations.
What happens next
The involved parties face a court-mandated deadline of October 7, 2026, to agree on a legal remedy regarding the infringement.
Further reading
For broader context on sector regulations, visit Healthcare.
More information
Review the full details of Judge Richard G Andrews's opinion regarding the case.
Source note: This article includes information reported by Financial Times News.
Live Poll
Should patent protections allow companies to force competitors to change drug labeling?
